SGEN Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 25.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Seagen Insider Trading History Chart

This chart shows the insider buying and selling history at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Seagen Share Price & Price History

Current Price: $228.74
Price Change: +0.30 (1.20%)
As of 01/9/2024 01:00 AM ET

This chart shows the closing price history over time for SGEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Seagen (NASDAQ:SGEN)

84.26% of Seagen stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SGEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$4B-$2B$0$2B$4BTotal InflowsTotal Outflows
Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Read More on Seagen

Today's Range

Now: $228.74
Low: $228.74
High: $228.74

50 Day Range

MA: $228.74
Low: $228.74
High: $228.74

52 Week Range

Now: $228.74
Low: $123.77
High: $228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Seagen?

Seagen's top insider investors include:
  1. David R Epstein (CEO)
  2. Todd E Simpson (CFO)
  3. Roger D Dansey (CMO)
  4. Jean I Liu (Insider)
  5. Charles R Romp (EVP)
  6. Vaughn B Himes (Insider)
  7. Daniel G Welch (Director)
Learn More about top insider investors at Seagen.